董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| J. David Joyner | 男 | President, Chief Executive Officer and Chair of the Board | 61 | 2121.41万美元 | 61.49 | 2026-05-14 |
| Guy P. Sansone | 男 | Independent Director | 61 | 33.50万美元 | 1.37 | 2026-05-14 |
| Alecia A. DeCoudreaux | 女 | Independent Director | 71 | 33.50万美元 | 4.34 | 2026-05-14 |
| Leslie V. Norwalk | 女 | Director | 60 | 未披露 | 未持股 | 2026-05-14 |
| Larry M. Robbins | 男 | Independent Director | 56 | 33.50万美元 | 858.30 | 2026-05-14 |
| Doug Shulman | 男 | Independent Director | 58 | 33.50万美元 | 0.59 | 2026-05-14 |
| Douglas H. Shulman | 男 | Independent Director | 58 | 未披露 | 未持股 | 2026-05-14 |
| Anne M. Finucane | 女 | Independent Director | 73 | 34.75万美元 | 3.94 | 2026-05-14 |
| Fernando Aguirre | 男 | Independent Director | 68 | 36.50万美元 | 4.16 | 2026-05-14 |
| C. David Brown II | 男 | Independent Director | 74 | 36.00万美元 | 21.32 | 2026-05-14 |
| Leslie V. Norwalk | 女 | Director | 60 | 33.50万美元 | 0.59 | 2026-05-14 |
| Michael F. Mahoney | 男 | Lead Independent Director | 61 | 42.17万美元 | 5.06 | 2026-05-14 |
| John E. Gallina | 男 | Independent Director | 66 | 未披露 | 61.49 | 2026-05-14 |
| J. Scott Kirby | 男 | Independent Director | 58 | 33.50万美元 | 1.30 | 2026-05-14 |
| Jeffrey R. Balser | 男 | Independent Director | 64 | 36.00万美元 | 1.37 | 2026-05-14 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Heidi B. Capozzi | 女 | Chief People Officer and Executive Vice President | 56 | 未披露 | 未持股 | 2026-05-14 |
| James D. Clark | -- | Chief Accounting Officer,Controller and Senior Vice President | 61 | 未披露 | 未持股 | 2026-05-14 |
| Brian O. Newman | 男 | Chief Financial Officer and Executive Vice President | 57 | 942.05万美元 | 0.0051 | 2026-05-14 |
| Prem S. Shah | -- | Executive Vice President and Group President | 46 | 1337.92万美元 | 59.01 | 2026-05-14 |
| Tilak Mandadi | 男 | Chief Experience and Technology Officer and Executive Vice President, Ventures | 62 | 1097.77万美元 | 21.15 | 2026-05-14 |
| Amy Compton Philips | -- | Chief Medical Officer and Executive Vice President | 62 | 未披露 | 未持股 | 2026-05-14 |
| Steven H. Nelson | 男 | Executive Vice President and President, Aetna | 67 | 1158.71万美元 | 6.94 | 2026-05-14 |
| Samrat S. Khichi | 男 | Chief Policy Officer and Executive Vice President and General Counsel | 59 | 1188.65万美元 | 未持股 | 2026-05-14 |
董事简历
中英对照 | 中文 | 英文- J. David Joyner
-
J. David Joyner，自2024年10月起担任Cvs Health Corporation的总裁兼首席执行官；从2023年1月到2024年10月，担任Cvs Health Corporation的执行副总裁兼药房服务总裁；从2021年7月到2023年9月担任健康技术公司gWell， Inc.的战略业务顾问；从2020年9月到2023年1月，担任Podimetrics Inc.（一家专注于糖尿病足溃疡识别和治疗的医疗保健公司）的顾问；自2020年7月起担任德克萨斯理工大学罗尔斯商学院咨询委员会成员；从2011年3月到2019年12月，CVS Health Corporation的Cvs Health Corporation销售和客户服务执行副总裁。
J. David Joyner has served as Chief Executive Officer and President of CVS Health since October 17, 2024 and was appointed Chair of the Board of CVS Health effective January 1, 2026. Prior to October 2024, Mr. Joyner had served as the Executive Vice President and President of Pharmacy Services of the Company since January 2023. From September 2020 to January 2023, Mr. Joyner served as an advisor to enterprises in the health care space. Mr. Joyner previously served in various roles at the Company and its predecessors, including as Executive Vice President – Sales and Account Services, CVS Caremark from 2004 through December 2019. Mr. Joyner began his career at Aetna in 1986 before joining Caremark Prescription Services in 1993. Mr. Joyner also has been a member of the Advisory Council of the Rawls College of Business of Texas Tech University since July 2020.B.S., The Rawls College of Business at Texas Tech University. - J. David Joyner，自2024年10月起担任Cvs Health Corporation的总裁兼首席执行官；从2023年1月到2024年10月，担任Cvs Health Corporation的执行副总裁兼药房服务总裁；从2021年7月到2023年9月担任健康技术公司gWell， Inc.的战略业务顾问；从2020年9月到2023年1月，担任Podimetrics Inc.（一家专注于糖尿病足溃疡识别和治疗的医疗保健公司）的顾问；自2020年7月起担任德克萨斯理工大学罗尔斯商学院咨询委员会成员；从2011年3月到2019年12月，CVS Health Corporation的Cvs Health Corporation销售和客户服务执行副总裁。
- J. David Joyner has served as Chief Executive Officer and President of CVS Health since October 17, 2024 and was appointed Chair of the Board of CVS Health effective January 1, 2026. Prior to October 2024, Mr. Joyner had served as the Executive Vice President and President of Pharmacy Services of the Company since January 2023. From September 2020 to January 2023, Mr. Joyner served as an advisor to enterprises in the health care space. Mr. Joyner previously served in various roles at the Company and its predecessors, including as Executive Vice President – Sales and Account Services, CVS Caremark from 2004 through December 2019. Mr. Joyner began his career at Aetna in 1986 before joining Caremark Prescription Services in 1993. Mr. Joyner also has been a member of the Advisory Council of the Rawls College of Business of Texas Tech University since July 2020.B.S., The Rawls College of Business at Texas Tech University.
- Guy P. Sansone
-
Guy P. Sansone，独立董事。他是H2 Health的联合创始人、董事长和首席执行官。他一直担任CVS Health董事（2024年11月以来）。此前，他曾担任纽约Alvarez & Marsal的董事总经理。他是几家公开交易和私人持有的医疗保健公司的董事会成员。他持有Albany， SUNY大学的学士学位。
Guy P. Sansone has served as the Co Founder, Chairman and Chief Executive Officer of H2 Health, a leading regional provider of physical rehabilitation services and clinician staffing solutions, since February 2020. Prior to that, he served as Managing Director at Alvarez & Marsal in New York, a financial advisory and consulting firm notable for its work in turnaround management and performance improvement of a number of large, high profile businesses across the globe, where he served as Chairman of the firm's Healthcare Industry Group, which he founded in 2004. Mr. Sansone is a member of the board of directors of several publicly traded and privately held health care companies, including Pediatrix Medical Group (formerly Mednax), a provider of physician services, Longevity Health Plans, a specialized Medicare Advantage health plan, Carisk Partners, a risk transfer, care coordination company, and ChenMed, an operator of medical centers. He formerly served on the board of directors of public company Magellan Healthcare and served on its audit and compliance committees.B.S., University at Albany, SUNY. - Guy P. Sansone，独立董事。他是H2 Health的联合创始人、董事长和首席执行官。他一直担任CVS Health董事（2024年11月以来）。此前，他曾担任纽约Alvarez & Marsal的董事总经理。他是几家公开交易和私人持有的医疗保健公司的董事会成员。他持有Albany， SUNY大学的学士学位。
- Guy P. Sansone has served as the Co Founder, Chairman and Chief Executive Officer of H2 Health, a leading regional provider of physical rehabilitation services and clinician staffing solutions, since February 2020. Prior to that, he served as Managing Director at Alvarez & Marsal in New York, a financial advisory and consulting firm notable for its work in turnaround management and performance improvement of a number of large, high profile businesses across the globe, where he served as Chairman of the firm's Healthcare Industry Group, which he founded in 2004. Mr. Sansone is a member of the board of directors of several publicly traded and privately held health care companies, including Pediatrix Medical Group (formerly Mednax), a provider of physician services, Longevity Health Plans, a specialized Medicare Advantage health plan, Carisk Partners, a risk transfer, care coordination company, and ChenMed, an operator of medical centers. He formerly served on the board of directors of public company Magellan Healthcare and served on its audit and compliance committees.B.S., University at Albany, SUNY.
- Alecia A. DeCoudreaux
-
Alecia A. DeCoudreaux自2011年7月以来是Mills College（男性和女性研究生项目的女性文理学院）的总裁。此前，她在Eli Lilly and Company（Eli Lilly）（全球药品制造商）担任许多领导角色，包括专业法律团队的副总裁和副总法律顾问（从2010年到2011年），Lilly美国的副总裁兼总法律顾问（从2005年到2009年），Eli Lilly的秘书、副总法律顾问（从1999年到2005年）。在Eli Lilly的30年职业生涯中，她也曾担任Lilly Research Laboratories的执行董事，联邦政府关系的主管，国家政府关系的主管和社区关系的主管。此外，她曾服务于一些慈善、教育、盈利和非盈利董事会，包括担任Wellesley College的理事和董事会主席。
Alecia A. DeCoudreaux is President Emerita of the former Mills College, a liberal arts college for women with graduate programs for women and men, which is now known as Mills College at Northeastern University, having served a five year term as President from July 2011 through June 2016. Previously, Ms. DeCoudreaux served in a number of leadership roles at Eli Lilly and Company, a global pharmaceutical manufacturer ("Eli Lilly"), including as Vice President and Deputy General Counsel, Specialty Legal Team, from 2010 2011, Vice President and General Counsel, Lilly USA, from 2005 2009, and Secretary and Deputy General Counsel of Eli Lilly from 1999 2005. During her 30 year career with Eli Lilly, Ms. DeCoudreaux also previously served as Executive Director of Lilly Research Laboratories, Director of Federal Government Relations, Director of State Government Relations and Director of Community Relations. In addition, Ms. DeCoudreaux has served on a number of charitable, educational, for profit and nonprofit boards, including as both a trustee and board chair at Wellesley College. She currently serves as Lead Independent Trustee and Chair of the Board of Trustees of Parnassus Funds/Parnassus Income Funds, a family of investment funds that integrates environmental, social and governance factors and fundamental investment principles.B.A., Wellesley College; J.D., Maurer School of Law at Indiana University. - Alecia A. DeCoudreaux自2011年7月以来是Mills College（男性和女性研究生项目的女性文理学院）的总裁。此前，她在Eli Lilly and Company（Eli Lilly）（全球药品制造商）担任许多领导角色，包括专业法律团队的副总裁和副总法律顾问（从2010年到2011年），Lilly美国的副总裁兼总法律顾问（从2005年到2009年），Eli Lilly的秘书、副总法律顾问（从1999年到2005年）。在Eli Lilly的30年职业生涯中，她也曾担任Lilly Research Laboratories的执行董事，联邦政府关系的主管，国家政府关系的主管和社区关系的主管。此外，她曾服务于一些慈善、教育、盈利和非盈利董事会，包括担任Wellesley College的理事和董事会主席。
- Alecia A. DeCoudreaux is President Emerita of the former Mills College, a liberal arts college for women with graduate programs for women and men, which is now known as Mills College at Northeastern University, having served a five year term as President from July 2011 through June 2016. Previously, Ms. DeCoudreaux served in a number of leadership roles at Eli Lilly and Company, a global pharmaceutical manufacturer ("Eli Lilly"), including as Vice President and Deputy General Counsel, Specialty Legal Team, from 2010 2011, Vice President and General Counsel, Lilly USA, from 2005 2009, and Secretary and Deputy General Counsel of Eli Lilly from 1999 2005. During her 30 year career with Eli Lilly, Ms. DeCoudreaux also previously served as Executive Director of Lilly Research Laboratories, Director of Federal Government Relations, Director of State Government Relations and Director of Community Relations. In addition, Ms. DeCoudreaux has served on a number of charitable, educational, for profit and nonprofit boards, including as both a trustee and board chair at Wellesley College. She currently serves as Lead Independent Trustee and Chair of the Board of Trustees of Parnassus Funds/Parnassus Income Funds, a family of investment funds that integrates environmental, social and governance factors and fundamental investment principles.B.A., Wellesley College; J.D., Maurer School of Law at Indiana University.
- Leslie V. Norwalk
-
Leslie Norwalk，非独立董事。她是Epstein， Becker & Green， P.C。的战略顾问，并自2024年11月起担任CVS Health的董事。她在医疗保健行业以及相关的政府法规、公司治理、医疗保健合规和风险管理方面拥有深厚的知识和经验。她是几家公司的董事会成员，包括Arvinas， Inc., ModivCare, Inc., Neurocrine Biosciences, Inc.和Globus Medical， Inc.。她持有Wellesley College的学士学位和George Mason大学的法学博士学位。
Leslie V. Norwalk has served as Strategic Counsel to health care companies at Epstein, Becker & Green, P.C., a national law firm, since 2007. She also advises companies through EBG Advisors, a national strategy and management consultancy, and National Health Advisors, an advocacy firm. She serves as an advisor to private equity investors, including three private equity firms, particularly on health care matters. Ms. Norwalk currently sits on the boards of directors of Arvinas, Inc., a biotechnology company, Neurocrine Biosciences, Inc., a biopharmaceutical company, and Globus Medical, Inc., a medical device company, and several privately held health care entities. She is also a member of APCO Worldwide's International Advisory Council. Ms. Norwalk formerly sat on the boards of NuVasive, Magellan Health, Centene and Endologix, among others, and is the former Acting Administrator for the U.S. Centers for Medicare & Medicaid Services ("CMS") under the George W. Bush administration.B.A., Wellesley College, J.D., George Mason University. - Leslie Norwalk，非独立董事。她是Epstein， Becker & Green， P.C。的战略顾问，并自2024年11月起担任CVS Health的董事。她在医疗保健行业以及相关的政府法规、公司治理、医疗保健合规和风险管理方面拥有深厚的知识和经验。她是几家公司的董事会成员，包括Arvinas， Inc., ModivCare, Inc., Neurocrine Biosciences, Inc.和Globus Medical， Inc.。她持有Wellesley College的学士学位和George Mason大学的法学博士学位。
- Leslie V. Norwalk has served as Strategic Counsel to health care companies at Epstein, Becker & Green, P.C., a national law firm, since 2007. She also advises companies through EBG Advisors, a national strategy and management consultancy, and National Health Advisors, an advocacy firm. She serves as an advisor to private equity investors, including three private equity firms, particularly on health care matters. Ms. Norwalk currently sits on the boards of directors of Arvinas, Inc., a biotechnology company, Neurocrine Biosciences, Inc., a biopharmaceutical company, and Globus Medical, Inc., a medical device company, and several privately held health care entities. She is also a member of APCO Worldwide's International Advisory Council. Ms. Norwalk formerly sat on the boards of NuVasive, Magellan Health, Centene and Endologix, among others, and is the former Acting Administrator for the U.S. Centers for Medicare & Medicaid Services ("CMS") under the George W. Bush administration.B.A., Wellesley College, J.D., George Mason University.
- Larry M. Robbins
-
Larry M. Robbins，是一名独立董事。他是Glenview Capital Management， LLC的创始人兼首席执行官。自2024年11月以来，他一直担任CVS Health的董事。此前，他在Omega Advisors担任了6年的分析师和合伙人。他于2000年创立了Glenview。自2021年以来，他一直担任Butterfly Network， Inc.的首席独立董事和董事会成员。他是教育改革的积极支持者，并在多个教育委员会任职。他拥有宾夕法尼亚大学的学士学位。
Larry M. Robbins is the Founder, Portfolio Manager and Chief Executive Officer of Glenview Capital Management, LLC. Prior to founding Glenview in 2000, Mr. Robbins spent six years as an analyst and partner at Omega Advisors on their U.S. equity long/short team. He joined Omega after three years at Gleacher & Company, a merger and acquisition advisory boutique in New York. For 30 years, Mr. Robbins has been a portfolio manager analyzing and advising leading publicly traded companies on financial reporting and controls, capital allocation and capital markets strategy and a broad range of governance, operational, communication and strategic issues. Mr. Robbins has been lead independent director and a member of the board of directors of Butterfly Network, Inc., a medical digital imaging company, since 2021. He is also an active supporter of education reform and serves as a board member of KIPP NYC, Relay Graduate School of Education and Zearn.B.S., University of Pennsylvania. - Larry M. Robbins，是一名独立董事。他是Glenview Capital Management， LLC的创始人兼首席执行官。自2024年11月以来，他一直担任CVS Health的董事。此前，他在Omega Advisors担任了6年的分析师和合伙人。他于2000年创立了Glenview。自2021年以来，他一直担任Butterfly Network， Inc.的首席独立董事和董事会成员。他是教育改革的积极支持者，并在多个教育委员会任职。他拥有宾夕法尼亚大学的学士学位。
- Larry M. Robbins is the Founder, Portfolio Manager and Chief Executive Officer of Glenview Capital Management, LLC. Prior to founding Glenview in 2000, Mr. Robbins spent six years as an analyst and partner at Omega Advisors on their U.S. equity long/short team. He joined Omega after three years at Gleacher & Company, a merger and acquisition advisory boutique in New York. For 30 years, Mr. Robbins has been a portfolio manager analyzing and advising leading publicly traded companies on financial reporting and controls, capital allocation and capital markets strategy and a broad range of governance, operational, communication and strategic issues. Mr. Robbins has been lead independent director and a member of the board of directors of Butterfly Network, Inc., a medical digital imaging company, since 2021. He is also an active supporter of education reform and serves as a board member of KIPP NYC, Relay Graduate School of Education and Zearn.B.S., University of Pennsylvania.
- Doug Shulman
-
Doug Shulman，独立董事。他是OneMain Holdings， Inc.的董事长兼首席执行官，自2024年11月起担任CVS Health董事。他曾在纽约梅隆银行、麦肯锡公司和美国金融业监管局担任领导职务。他持有Williams College的学士学位，Harvard JFK政府学院的硕士学位，以及Georgetown大学的法学博士学位。
Doug Shulman,is an Independent Director. He is the Chairman and Chief Executive Officer of OneMain Holdings, Inc. and has been a CVS Health director since November 2024. He previously held leadership roles at BNY Mellon, McKinsey & Company, and FINRA. He holds a B.A. from Williams College, an M.P.A. from Harvard JFK School of Government, and a J.D. from Georgetown University. - Doug Shulman，独立董事。他是OneMain Holdings， Inc.的董事长兼首席执行官，自2024年11月起担任CVS Health董事。他曾在纽约梅隆银行、麦肯锡公司和美国金融业监管局担任领导职务。他持有Williams College的学士学位，Harvard JFK政府学院的硕士学位，以及Georgetown大学的法学博士学位。
- Doug Shulman,is an Independent Director. He is the Chairman and Chief Executive Officer of OneMain Holdings, Inc. and has been a CVS Health director since November 2024. He previously held leadership roles at BNY Mellon, McKinsey & Company, and FINRA. He holds a B.A. from Williams College, an M.P.A. from Harvard JFK School of Government, and a J.D. from Georgetown University.
- Douglas H. Shulman
-
Douglas H. Shulman自2018年起担任Onemain Holdings, Inc.的首席执行官，该公司是一家专注于消费者的金融服务公司，在为非主要客户提供负责任的信贷服务方面处于领先地位，并自2021年起担任OneMain的董事会主席。在加入OneMain之前，Shulman先生是高级执行副总裁、客户服务交付全球主管，并且是全球金融服务公司纽约梅隆银行执行委员会成员。在加入纽约梅隆银行之前，他是麦肯锡公司的高级顾问，2008年至2012年，他担任美国国税局局长，在那里他指导了该机构技术的转型，将客户服务指标推向历史水平，并在解决国际逃税问题方面引领了重要突破。Shulman先生此前担任FINRA及其前身公司NASD的副主席，在此之前担任市场、服务和信息总裁，当时该公司拥有纳斯达克股票市场和美国证券交易所。B.A.，威廉姆斯学院，MBA，哈佛肯尼迪政府学院，法学博士，乔治城大学。
Douglas H. Shulman has served as Chief Executive Officer of OneMain Holdings, Inc., a consumer focused financial services company that is a leader in offering nonprime customers responsible access to credit, since 2018, and has been Chairman of the Board of OneMain since 2021. Prior to joining OneMain, Mr. Shulman was Senior Executive Vice President, Global Head of Client Service Delivery and was a member of the Executive Committee at BNY Mellon, a global financial services firm. Prior to BNY Mellon, he was a Senior Advisor at McKinsey & Company, and from 2008 to 2012, he served as the Commissioner of the Internal Revenue Service, where he directed a transformation of the agency's technology, drove customer service metrics to historic levels and led important breakthroughs in addressing international tax evasion. Previously, Mr. Shulman was Vice Chairman and, before that, President of Markets, Services and Information at FINRA and its predecessor company, NASD, when it owned the Nasdaq Stock Market and the American Stock Exchange.B.A., Williams College, M.P.A., Harvard JFK School of Government, J.D., Georgetown University. - Douglas H. Shulman自2018年起担任Onemain Holdings, Inc.的首席执行官，该公司是一家专注于消费者的金融服务公司，在为非主要客户提供负责任的信贷服务方面处于领先地位，并自2021年起担任OneMain的董事会主席。在加入OneMain之前，Shulman先生是高级执行副总裁、客户服务交付全球主管，并且是全球金融服务公司纽约梅隆银行执行委员会成员。在加入纽约梅隆银行之前，他是麦肯锡公司的高级顾问，2008年至2012年，他担任美国国税局局长，在那里他指导了该机构技术的转型，将客户服务指标推向历史水平，并在解决国际逃税问题方面引领了重要突破。Shulman先生此前担任FINRA及其前身公司NASD的副主席，在此之前担任市场、服务和信息总裁，当时该公司拥有纳斯达克股票市场和美国证券交易所。B.A.，威廉姆斯学院，MBA，哈佛肯尼迪政府学院，法学博士，乔治城大学。
- Douglas H. Shulman has served as Chief Executive Officer of OneMain Holdings, Inc., a consumer focused financial services company that is a leader in offering nonprime customers responsible access to credit, since 2018, and has been Chairman of the Board of OneMain since 2021. Prior to joining OneMain, Mr. Shulman was Senior Executive Vice President, Global Head of Client Service Delivery and was a member of the Executive Committee at BNY Mellon, a global financial services firm. Prior to BNY Mellon, he was a Senior Advisor at McKinsey & Company, and from 2008 to 2012, he served as the Commissioner of the Internal Revenue Service, where he directed a transformation of the agency's technology, drove customer service metrics to historic levels and led important breakthroughs in addressing international tax evasion. Previously, Mr. Shulman was Vice Chairman and, before that, President of Markets, Services and Information at FINRA and its predecessor company, NASD, when it owned the Nasdaq Stock Market and the American Stock Exchange.B.A., Williams College, M.P.A., Harvard JFK School of Government, J.D., Georgetown University.
- Anne M. Finucane
-
Anne M. Finucane，自2022年起担任Rubicon Carbon主席和TPG气候基金高级顾问，此前她曾担任美国银行副董事长（2015-2021年），领导ESG和可持续金融倡议。她目前在西维斯健康和威廉索诺玛的董事会任职（自2011年起）。Finucane女士拥有新罕布什尔大学的学士学位。
Anne M. Finucane has been a Senior Advisor of the TPG Climate Rise Fund ("TPG"), an investment fund focused on various climate sub sectors, since September 2022 and the Chair of the Board of Rubicon Carbon, a carbon credit firm and a TPG portfolio company, since November 2022. Previously, Ms. Finucane served as Chairman of the Board of Bank of America Europe from July 2018 through December 2022. Ms. Finucane served as a Vice Chairman of Bank of America Corporation, an international financial services company, from July 2015 until her retirement in December 2021. From 2006 through July 2015, Ms. Finucane served as Global Chief Strategy and Marketing Officer for Bank of America and served as Northeast Market President from 2004 through July 2015. As a member of the executive management team, Ms. Finucane was responsible for the strategic positioning of Bank of America and led the company's environmental, social and governance, sustainable finance, capital deployment and global public policy efforts. She established and co chaired the company's Sustainable Finance Committee, which included a $1 trillion environmental business initiative, deploying capital to help accelerate the transition to a low carbon, sustainable economy, and was chair of Bank of America's Environmental, Social and Governance Committee. She currently serves as a director of Williams Sonoma, Inc., a retailer of kitchen and home products.B.A., University of New Hampshire. - Anne M. Finucane，自2022年起担任Rubicon Carbon主席和TPG气候基金高级顾问，此前她曾担任美国银行副董事长（2015-2021年），领导ESG和可持续金融倡议。她目前在西维斯健康和威廉索诺玛的董事会任职（自2011年起）。Finucane女士拥有新罕布什尔大学的学士学位。
- Anne M. Finucane has been a Senior Advisor of the TPG Climate Rise Fund ("TPG"), an investment fund focused on various climate sub sectors, since September 2022 and the Chair of the Board of Rubicon Carbon, a carbon credit firm and a TPG portfolio company, since November 2022. Previously, Ms. Finucane served as Chairman of the Board of Bank of America Europe from July 2018 through December 2022. Ms. Finucane served as a Vice Chairman of Bank of America Corporation, an international financial services company, from July 2015 until her retirement in December 2021. From 2006 through July 2015, Ms. Finucane served as Global Chief Strategy and Marketing Officer for Bank of America and served as Northeast Market President from 2004 through July 2015. As a member of the executive management team, Ms. Finucane was responsible for the strategic positioning of Bank of America and led the company's environmental, social and governance, sustainable finance, capital deployment and global public policy efforts. She established and co chaired the company's Sustainable Finance Committee, which included a $1 trillion environmental business initiative, deploying capital to help accelerate the transition to a low carbon, sustainable economy, and was chair of Bank of America's Environmental, Social and Governance Committee. She currently serves as a director of Williams Sonoma, Inc., a retailer of kitchen and home products.B.A., University of New Hampshire.
- Fernando Aguirre
-
Fernando Aguirre，自2019年7月起担任董事。2004年1月至2012年10月，他担任Chiquita Brands International， Inc.的总裁兼首席执行官；2004年5月至2012年10月，他担任董事长。在此之前，他从1980年到2004年在宝洁公司担任各种全球营销和管理职务。他目前是CVS Health（一家上市的美国医疗保健公司，拥有CVS Pharmacy、CVS Caremark和Aetna）的董事会成员；百乐嘉利宝是一家上市公司，是世界上最大的可可加工商和巧克力制造商之一。他曾任职于其他董事会，包括Aetna， Inc.， Coca-Cola Enterprises和Levi Strauss & Co.。Aguirre先生目前是Erie seawwolves Minor League棒球队（底特律老虎队的双AA附属球队）的所有者和首席执行官。他还拥有默特尔比奇鹈鹕队（Myrtle Beach Pelicans）的少数股权，这是芝加哥小熊队（Chicago Cubs）的低a级球队。Aguirre先生是墨西哥人，是西班牙裔社区的杰出人物，被西班牙裔商业杂志评为100位影响力人物之一，并被NFL授予西班牙裔传统领导奖。他持有Southern Illinois University Edwardsville的学士学位。
Fernando Aguirre served as President and CEO of Chiquita Brands International, Inc. (January 2004 to October 2012) and also served as chair of the board (May 2004 to October 2012). Prior to that, Mr. Aguirre held various global marketing and management roles at Procter & Gamble (1980 to 2004).Mr. Aguirre currently serves on two other public company boards: CVS Health, an American healthcare company that owns CVS Pharmacy, CVS Caremark and Aetna; and Barry Callebaut, one of the world's largest cocoa processors and chocolate manufacturers. He previously served on several other boards including Aetna, Inc., Coca Cola Enterprises and Levi Strauss & Co.Mr. Aguirre is currently the Owner and CEO of the Erie SeaWolves Minor League Baseball team, the double AA affiliate of the Detroit Tigers. He also owns a minority stake in the Myrtle Beach Pelicans, a low A affiliate of the Chicago Cubs. A native of Mexico, Mr. Aguirre is a prominent figure in the Hispanic community, recognized as one of the 100 Influentials by Hispanic Business Magazine and honored with the Hispanic Heritage Leadership Award by the National Football League. Mr. Aguirre received a B.S. from Southern Illinois University Edwardsville. - Fernando Aguirre，自2019年7月起担任董事。2004年1月至2012年10月，他担任Chiquita Brands International， Inc.的总裁兼首席执行官；2004年5月至2012年10月，他担任董事长。在此之前，他从1980年到2004年在宝洁公司担任各种全球营销和管理职务。他目前是CVS Health（一家上市的美国医疗保健公司，拥有CVS Pharmacy、CVS Caremark和Aetna）的董事会成员；百乐嘉利宝是一家上市公司，是世界上最大的可可加工商和巧克力制造商之一。他曾任职于其他董事会，包括Aetna， Inc.， Coca-Cola Enterprises和Levi Strauss & Co.。Aguirre先生目前是Erie seawwolves Minor League棒球队（底特律老虎队的双AA附属球队）的所有者和首席执行官。他还拥有默特尔比奇鹈鹕队（Myrtle Beach Pelicans）的少数股权，这是芝加哥小熊队（Chicago Cubs）的低a级球队。Aguirre先生是墨西哥人，是西班牙裔社区的杰出人物，被西班牙裔商业杂志评为100位影响力人物之一，并被NFL授予西班牙裔传统领导奖。他持有Southern Illinois University Edwardsville的学士学位。
- Fernando Aguirre served as President and CEO of Chiquita Brands International, Inc. (January 2004 to October 2012) and also served as chair of the board (May 2004 to October 2012). Prior to that, Mr. Aguirre held various global marketing and management roles at Procter & Gamble (1980 to 2004).Mr. Aguirre currently serves on two other public company boards: CVS Health, an American healthcare company that owns CVS Pharmacy, CVS Caremark and Aetna; and Barry Callebaut, one of the world's largest cocoa processors and chocolate manufacturers. He previously served on several other boards including Aetna, Inc., Coca Cola Enterprises and Levi Strauss & Co.Mr. Aguirre is currently the Owner and CEO of the Erie SeaWolves Minor League Baseball team, the double AA affiliate of the Detroit Tigers. He also owns a minority stake in the Myrtle Beach Pelicans, a low A affiliate of the Chicago Cubs. A native of Mexico, Mr. Aguirre is a prominent figure in the Hispanic community, recognized as one of the 100 Influentials by Hispanic Business Magazine and honored with the Hispanic Heritage Leadership Award by the National Football League. Mr. Aguirre received a B.S. from Southern Illinois University Edwardsville.
- C. David Brown II
-
C. David Brown II，自2000年3月起担任Broad and Cassel（佛罗里达州律师事务所）的董事长。从1989年到2000年3月，他是公司奥兰多办事处的管理合伙人。他也是Rayonier Advanced Materials Inc.的首席董事。RYAM是一家领先的特种纤维素生产公司。他曾担任Rayonier Inc.（一家房地产开发和林地管理公司）的董事会成员和首席董事（2014年6月RYAM分拆之前）。从2015年4月到2016年9月，他还担任ITT Educational Services， Inc.（一个面向技术的本科和研究生学位课程的国家供应商）的董事。2001年3月起，Brown先生担任Caremark Rx， Inc.的董事会成员，直到涉及CVS Health和Caremark的合并交易完成，当时他成为CVS Health的董事。Brown先生拥有佛罗里达大学的博士学位。
C. David Brown II has been a partner of Nelson Mullins Riley & Scarborough LLP ("Nelson Mullins"), a national law firm, since the August 2018 merger of Nelson Mullins and the Florida based Broad and Cassel, of which Mr. Brown was Chairman from March 2000 through the time of the merger. He was also a member of the executive committee of Nelson Mullins until he rotated off the committee in December 2021. He served as the lead director of Rayonier Advanced Materials Inc., a leading specialty cellulose production company, until his retirement from that board in May 2020. Mr. Brown previously served on the board of Caremark Rx, Inc. from March 2001 until the closing of the merger transaction involving CVS Health and Caremark, when he became a director of CVS Health.B.S.B.A., University of Florida; J.D., University of Florida College of Law. - C. David Brown II，自2000年3月起担任Broad and Cassel（佛罗里达州律师事务所）的董事长。从1989年到2000年3月，他是公司奥兰多办事处的管理合伙人。他也是Rayonier Advanced Materials Inc.的首席董事。RYAM是一家领先的特种纤维素生产公司。他曾担任Rayonier Inc.（一家房地产开发和林地管理公司）的董事会成员和首席董事（2014年6月RYAM分拆之前）。从2015年4月到2016年9月，他还担任ITT Educational Services， Inc.（一个面向技术的本科和研究生学位课程的国家供应商）的董事。2001年3月起，Brown先生担任Caremark Rx， Inc.的董事会成员，直到涉及CVS Health和Caremark的合并交易完成，当时他成为CVS Health的董事。Brown先生拥有佛罗里达大学的博士学位。
- C. David Brown II has been a partner of Nelson Mullins Riley & Scarborough LLP ("Nelson Mullins"), a national law firm, since the August 2018 merger of Nelson Mullins and the Florida based Broad and Cassel, of which Mr. Brown was Chairman from March 2000 through the time of the merger. He was also a member of the executive committee of Nelson Mullins until he rotated off the committee in December 2021. He served as the lead director of Rayonier Advanced Materials Inc., a leading specialty cellulose production company, until his retirement from that board in May 2020. Mr. Brown previously served on the board of Caremark Rx, Inc. from March 2001 until the closing of the merger transaction involving CVS Health and Caremark, when he became a director of CVS Health.B.S.B.A., University of Florida; J.D., University of Florida College of Law.
- Leslie V. Norwalk
-
Leslie V. Norwalk，2012年5月起担任董事长。2013年2月起，她还担任遵约委员会成员。她现在是Epstein Becker Green、EBG Advisors和National Health Advisors战略顾问。2008年起，她一直担任私人股权公司Warburg Pincus、Ferrer Freeman & Company和Enhanced Equity Fund顾问。2015年5月起，她担任Endologix, Inc.董事长；2014年5月起担任NuVasive, Inc.董事长；2013年起担任Adobe Healthcare和 STARUS Medical Group董事长；2012年起担任LWU Medical Faculty Associates董事长；2011年起担任Volcano Corporation董事长；2010年起担任Ika Systems Corporation董事长。她曾在George H.W.Bush政府任职，自2006年到2007年担任CMS代理管理员。她获得了Wellesley College文学士学位和George Mason University School of Law 法学博士。
Leslie V. Norwalk,Since September 2007, Ms. Norwalk has served as Strategic Counsel to Epstein Becker & Green, P.C. From 2001 to 2007, Ms. Norwalk served the Bush Administration in the Centers for Medicare & Medicaid Services (CMS). From 2006 to 2007, she was the Acting Administrator, where she managed the operations of federal health care programs, including Medicare and Medicaid. For the four years prior to that position, she was the agency's Deputy Administrator. Prior to serving the Bush Administration, Ms. Norwalk practiced law with Epstein Becker & Green, P.C. where she advised clients on a variety of healthcare policy matters. She also served the first Bush administration in the White House Office of Presidential Personnel and the Office of the U.S. Trade Representative. Ms. Norwalk is currently a director on the public company boards of NuVasive Inc., a medical device company, Neurocrine Biosciences, Inc., a biopharmaceutical company, and Arvinas Inc., a clinical-stage biopharmaceutical company. She also serves as an Advisor to several private equity funds. She received a bachelor's degree from Wellesley College and a juris doctor degree from George Mason University School of Law. - Leslie V. Norwalk，2012年5月起担任董事长。2013年2月起，她还担任遵约委员会成员。她现在是Epstein Becker Green、EBG Advisors和National Health Advisors战略顾问。2008年起，她一直担任私人股权公司Warburg Pincus、Ferrer Freeman & Company和Enhanced Equity Fund顾问。2015年5月起，她担任Endologix, Inc.董事长；2014年5月起担任NuVasive, Inc.董事长；2013年起担任Adobe Healthcare和 STARUS Medical Group董事长；2012年起担任LWU Medical Faculty Associates董事长；2011年起担任Volcano Corporation董事长；2010年起担任Ika Systems Corporation董事长。她曾在George H.W.Bush政府任职，自2006年到2007年担任CMS代理管理员。她获得了Wellesley College文学士学位和George Mason University School of Law 法学博士。
- Leslie V. Norwalk,Since September 2007, Ms. Norwalk has served as Strategic Counsel to Epstein Becker & Green, P.C. From 2001 to 2007, Ms. Norwalk served the Bush Administration in the Centers for Medicare & Medicaid Services (CMS). From 2006 to 2007, she was the Acting Administrator, where she managed the operations of federal health care programs, including Medicare and Medicaid. For the four years prior to that position, she was the agency's Deputy Administrator. Prior to serving the Bush Administration, Ms. Norwalk practiced law with Epstein Becker & Green, P.C. where she advised clients on a variety of healthcare policy matters. She also served the first Bush administration in the White House Office of Presidential Personnel and the Office of the U.S. Trade Representative. Ms. Norwalk is currently a director on the public company boards of NuVasive Inc., a medical device company, Neurocrine Biosciences, Inc., a biopharmaceutical company, and Arvinas Inc., a clinical-stage biopharmaceutical company. She also serves as an Advisor to several private equity funds. She received a bachelor's degree from Wellesley College and a juris doctor degree from George Mason University School of Law.
- Michael F. Mahoney
-
Michael F. Mahoney，自2012年11月起担任总裁、首席执行官兼董事。他是波士顿科学国际有限公司的董事长、总裁兼首席执行官，自2023年11月起担任CVS Health Corporation董事。2011年10月17日起直到其现任职位期间，他担任公司总裁。作为公司的董事长，他专门负责心脏节律管理业务和内镜企业业务，以及某些固定企业要求。在加入该公司前， 2011年1月到2011年9月他是强生公司医疗设备和诊断部门全球主席，负责监督50000名员工和专营七家公司。2007年4月至2011年1月，Mahoney先生担任强生公司特许经营公司帝普公司的全球集团董事长，负责骨科和神经科学业务。2001年1月至2007年3月，Mahoney先生担任全球医疗护理用品交易所（ GHX ）总裁兼首席执行官，这是一提供汇集了医院、制造商、分销商和GPO的供应链方案和服务的供应商。Mahoney先生的职业生涯始于通用电气医疗器械集团，在那里他工作了12年，最高职位是医疗保健信息技术业务的总经理。Mahoney先生持有爱荷华大学的金融学工商管理学士和维克森林大学的工商管理硕士学位。
Michael F. Mahoney has been the President of Boston Scientific Corporation ("Boston Scientific"), a global developer, manufacturer and marketer of medical devices, since October 2011, and has been Chief Executive Officer and a member of the Board of Directors of Boston Scientific since November 2012. He became Chairman of the Board of Directors of Boston Scientific in May 2016. Prior to joining Boston Scientific, Mr. Mahoney served as Worldwide Company Group Chairman of Johnson & Johnson's DePuy franchise, an orthopedics and neurosciences business, from April 2007 through January 2011. From January 2001 through March 2007, he served as President and Chief Executive Officer of Global Healthcare Exchange, a leading medical supply chain solutions company. Mr. Mahoney began his career at General Electric Medical Systems, where he spent 12 years, culminating in the role of General Manager of the Healthcare Information Technology business. From October 2015 until September 2023, Mr. Mahoney served as a member of the Board of Directors of Baxter International Inc.B.B.A., University of Iowa; M.B.A., Wake Forest University. - Michael F. Mahoney，自2012年11月起担任总裁、首席执行官兼董事。他是波士顿科学国际有限公司的董事长、总裁兼首席执行官，自2023年11月起担任CVS Health Corporation董事。2011年10月17日起直到其现任职位期间，他担任公司总裁。作为公司的董事长，他专门负责心脏节律管理业务和内镜企业业务，以及某些固定企业要求。在加入该公司前， 2011年1月到2011年9月他是强生公司医疗设备和诊断部门全球主席，负责监督50000名员工和专营七家公司。2007年4月至2011年1月，Mahoney先生担任强生公司特许经营公司帝普公司的全球集团董事长，负责骨科和神经科学业务。2001年1月至2007年3月，Mahoney先生担任全球医疗护理用品交易所（ GHX ）总裁兼首席执行官，这是一提供汇集了医院、制造商、分销商和GPO的供应链方案和服务的供应商。Mahoney先生的职业生涯始于通用电气医疗器械集团，在那里他工作了12年，最高职位是医疗保健信息技术业务的总经理。Mahoney先生持有爱荷华大学的金融学工商管理学士和维克森林大学的工商管理硕士学位。
- Michael F. Mahoney has been the President of Boston Scientific Corporation ("Boston Scientific"), a global developer, manufacturer and marketer of medical devices, since October 2011, and has been Chief Executive Officer and a member of the Board of Directors of Boston Scientific since November 2012. He became Chairman of the Board of Directors of Boston Scientific in May 2016. Prior to joining Boston Scientific, Mr. Mahoney served as Worldwide Company Group Chairman of Johnson & Johnson's DePuy franchise, an orthopedics and neurosciences business, from April 2007 through January 2011. From January 2001 through March 2007, he served as President and Chief Executive Officer of Global Healthcare Exchange, a leading medical supply chain solutions company. Mr. Mahoney began his career at General Electric Medical Systems, where he spent 12 years, culminating in the role of General Manager of the Healthcare Information Technology business. From October 2015 until September 2023, Mr. Mahoney served as a member of the Board of Directors of Baxter International Inc.B.B.A., University of Iowa; M.B.A., Wake Forest University.
- John E. Gallina
-
John E. Gallina ，他曾担任高级副总裁、财务总监、首席财务官和首席风险官（自2011年5月以来）。自1994年以来，他担任美国众多的财务职务。以前，他担任负责内部审计和持续改进的高级副总裁（2010年3月以来）、高级财务副总裁（2008年8月以来）和临时首席财务官（从2008年4月到2008年9月）。同时，他曾担任全面健康解决方案业务单位的首席财务官（从2008年1月到2010年1月）。之前，他担任副总裁，负责企业财务计划和分析（从2000年11月到2008年1月）。
John E. Gallina is the former Executive Vice President and Chief Financial Officer of Elevance Health, Inc. ("Elevance"), a leading health benefits provider, a position he held from June 2016 through November 1, 2023. He then served as Executive Vice President and Advisor to the CEO from November 2023 until May 2024, when he retired from Elevance. Prior to serving as CFO, Mr. Gallina held various roles at Elevance in the Internal Audit, Accounting and Finance areas, having started with that company in 1994. Prior to that he was a senior audit manager at Coopers & Lybrand and a certified public accountant. Mr. Gallina currently serves as a director and chair of the audit committee of Arrive AI Inc., a developmental technology company with a focus on autonomous deliveries.B.S., Business Administration, The Ohio State University. - John E. Gallina ，他曾担任高级副总裁、财务总监、首席财务官和首席风险官（自2011年5月以来）。自1994年以来，他担任美国众多的财务职务。以前，他担任负责内部审计和持续改进的高级副总裁（2010年3月以来）、高级财务副总裁（2008年8月以来）和临时首席财务官（从2008年4月到2008年9月）。同时，他曾担任全面健康解决方案业务单位的首席财务官（从2008年1月到2010年1月）。之前，他担任副总裁，负责企业财务计划和分析（从2000年11月到2008年1月）。
- John E. Gallina is the former Executive Vice President and Chief Financial Officer of Elevance Health, Inc. ("Elevance"), a leading health benefits provider, a position he held from June 2016 through November 1, 2023. He then served as Executive Vice President and Advisor to the CEO from November 2023 until May 2024, when he retired from Elevance. Prior to serving as CFO, Mr. Gallina held various roles at Elevance in the Internal Audit, Accounting and Finance areas, having started with that company in 1994. Prior to that he was a senior audit manager at Coopers & Lybrand and a certified public accountant. Mr. Gallina currently serves as a director and chair of the audit committee of Arrive AI Inc., a developmental technology company with a focus on autonomous deliveries.B.S., Business Administration, The Ohio State University.
- J. Scott Kirby
-
J. Scott Kirby，United Airlines Holdings, Inc.：首席执行官（2020年至今）、总裁（2016-2020年）；美国航空集团和美国；Airlines，Inc.（航空公司）：总裁（2013-2016年）；US Airways（航空公司）：总裁（2006-2013年）。学历：乔治华盛顿大学，硕士，运筹学、美国空军学院、学士，计算机科学与运筹学。
J. Scott Kirby has been the Chief Executive Officer and a member of the Board of Directors of United Airlines Holdings, Inc. ("United Airlines"), an international air carrier, since May 2020. Mr. Kirby also serves on the Executive Committee and the Finance Committee of the United Airlines Board of Directors. From August 2016 until May 2020, Mr. Kirby was President of United Airlines and was responsible for its operations, marketing, sales, alliances, network planning and revenue management. Prior to joining United Airlines, he was President of American Airlines from December 2013 until August 2016 and was President of US Airways from September 2006 until December 2013, when US Airways merged with American Airlines. He started his career at the Pentagon and in the technology sector. He is former Chairman of the Star Alliance Chief Executive Board, a global alliance consisting of 25 member airlines, and is a member of the Board of Governors of the International Air Transport Association, a trade association comprised of 360 of the world's airlines. Mr. Kirby is also a member of the Board of Directors of the U.S. Air Force Academy Foundation.B.S., U.S. Air Force Academy; M.S., George Washington University. - J. Scott Kirby，United Airlines Holdings, Inc.：首席执行官（2020年至今）、总裁（2016-2020年）；美国航空集团和美国；Airlines，Inc.（航空公司）：总裁（2013-2016年）；US Airways（航空公司）：总裁（2006-2013年）。学历：乔治华盛顿大学，硕士，运筹学、美国空军学院、学士，计算机科学与运筹学。
- J. Scott Kirby has been the Chief Executive Officer and a member of the Board of Directors of United Airlines Holdings, Inc. ("United Airlines"), an international air carrier, since May 2020. Mr. Kirby also serves on the Executive Committee and the Finance Committee of the United Airlines Board of Directors. From August 2016 until May 2020, Mr. Kirby was President of United Airlines and was responsible for its operations, marketing, sales, alliances, network planning and revenue management. Prior to joining United Airlines, he was President of American Airlines from December 2013 until August 2016 and was President of US Airways from September 2006 until December 2013, when US Airways merged with American Airlines. He started his career at the Pentagon and in the technology sector. He is former Chairman of the Star Alliance Chief Executive Board, a global alliance consisting of 25 member airlines, and is a member of the Board of Governors of the International Air Transport Association, a trade association comprised of 360 of the world's airlines. Mr. Kirby is also a member of the Board of Directors of the U.S. Air Force Academy Foundation.B.S., U.S. Air Force Academy; M.S., George Washington University.
- Jeffrey R. Balser
-
Jeffrey R. Balser，2016年起担任范德比尔特大学医学中心总裁兼首席执行官，2008年起担任范德比尔特大学医学院院长。美国国家医学研究院院士，他此前曾担任瓦里安医疗董事会成员（2018-2021年）。Balser博士拥有杜兰大学学士学位和范德比尔特大学医学博士学位。
Jeffrey R. Balser has served as the chief executive of Vanderbilt University Medical Center ("VUMC") since 2009 and has been President and Chief Executive Officer since 2016, when VUMC became an independent health care company. He has also served as the Dean of the Vanderbilt University School of Medicine since 2008. Dr. Balser is an elected member of the National Academy of Medicine and served two terms on its governing council. He previously served on the board of Varian Medical Systems, Inc., an oncology treatment device and software maker that was publicly traded, from October 2018 until Varian was acquired by Siemens Healthineers AG in April 2021.B.S., Tulane University; M.D. and Ph.D., Vanderbilt University. - Jeffrey R. Balser，2016年起担任范德比尔特大学医学中心总裁兼首席执行官，2008年起担任范德比尔特大学医学院院长。美国国家医学研究院院士，他此前曾担任瓦里安医疗董事会成员（2018-2021年）。Balser博士拥有杜兰大学学士学位和范德比尔特大学医学博士学位。
- Jeffrey R. Balser has served as the chief executive of Vanderbilt University Medical Center ("VUMC") since 2009 and has been President and Chief Executive Officer since 2016, when VUMC became an independent health care company. He has also served as the Dean of the Vanderbilt University School of Medicine since 2008. Dr. Balser is an elected member of the National Academy of Medicine and served two terms on its governing council. He previously served on the board of Varian Medical Systems, Inc., an oncology treatment device and software maker that was publicly traded, from October 2018 until Varian was acquired by Siemens Healthineers AG in April 2021.B.S., Tulane University; M.D. and Ph.D., Vanderbilt University.
高管简历
中英对照 | 中文 | 英文- Heidi B. Capozzi
Heidi B. Capozzi， 曾一直担任高级副总裁，负责人力资源（2016年3月以来）。她此前曾担任领导力发展、人才管理和组织有效性副总裁（2013年4月至2016年3月）、Commercial Airplanes的飞机项目部门的人力资源主管（2011年4月至2013年4月）、Boeing Military Aircraft的监督和参与部门的人力资源主管（2009年5月至2011年4月）。
Heidi B. Capozzi previously served as Vice President of Leadership Development, Talent Management and Organization Effectiveness from April 2013 to March 2016; Director of Human Resources for the Airplane Programs division of Commercial Airplanes from April 2011 to April 2013; and Director of Human Resources for the Surveillance and Engagement division of Boeing Military Aircraft from May 2009 to April 2011.- Heidi B. Capozzi， 曾一直担任高级副总裁，负责人力资源（2016年3月以来）。她此前曾担任领导力发展、人才管理和组织有效性副总裁（2013年4月至2016年3月）、Commercial Airplanes的飞机项目部门的人力资源主管（2011年4月至2013年4月）、Boeing Military Aircraft的监督和参与部门的人力资源主管（2009年5月至2011年4月）。
- Heidi B. Capozzi previously served as Vice President of Leadership Development, Talent Management and Organization Effectiveness from April 2013 to March 2016; Director of Human Resources for the Airplane Programs division of Commercial Airplanes from April 2011 to April 2013; and Director of Human Resources for the Surveillance and Engagement division of Boeing Military Aircraft from May 2009 to April 2011.
- James D. Clark
James D. Clark自2018年11月起担任CVS Health Corporation高级副总裁-财务总监兼首席会计官James D.Clark； 从2009年9月至2018年10月，CVS Pharmacy，Inc.财务和会计副总裁。
James D. Clark,Senior Vice President - Controller and Chief Accounting Officer of CVS Health Corporation since November 2018; Vice President - Finance and Accounting of CVS Pharmacy, Inc. from September 2009 through October 2018.- James D. Clark自2018年11月起担任CVS Health Corporation高级副总裁-财务总监兼首席会计官James D.Clark； 从2009年9月至2018年10月，CVS Pharmacy，Inc.财务和会计副总裁。
- James D. Clark,Senior Vice President - Controller and Chief Accounting Officer of CVS Health Corporation since November 2018; Vice President - Finance and Accounting of CVS Pharmacy, Inc. from September 2009 through October 2018.
- Brian O. Newman
Brian O. Newman，2019年至今首席财务官兼财务主管，百事可乐公司拉丁美洲和财务执行副总裁（2017年至2019年），百事可乐公司全球运营执行副总裁（2015年至2017年）， 百事可乐公司全球电子商务主管（2014-2015）。
Brian O. Newman has served as Executive Vice President and Chief Financial Officer of CVS Health Corporation ("CVS Health"), a health solutions company, since May 2025. Prior to joining CVS Health, he served as Executive Vice President and Chief Financial Officer of United Parcel Service, Inc. ("UPS"), a global package delivery company and provider of supply chain management solutions, from 2019 until May 2024. Prior to joining UPS, Mr. Newman spent 26 years at PepsiCo, where he served in a variety of finance leadership roles spanning Europe, Asia and North and South America. He also served as Executive Vice President for PepsiCo's Global Operations, responsible for global operations including supply chain, global procurement, global security, enterprise risk management and transformation, and as PepsiCo's Chief Strategy Officer.- Brian O. Newman，2019年至今首席财务官兼财务主管，百事可乐公司拉丁美洲和财务执行副总裁（2017年至2019年），百事可乐公司全球运营执行副总裁（2015年至2017年）， 百事可乐公司全球电子商务主管（2014-2015）。
- Brian O. Newman has served as Executive Vice President and Chief Financial Officer of CVS Health Corporation ("CVS Health"), a health solutions company, since May 2025. Prior to joining CVS Health, he served as Executive Vice President and Chief Financial Officer of United Parcel Service, Inc. ("UPS"), a global package delivery company and provider of supply chain management solutions, from 2019 until May 2024. Prior to joining UPS, Mr. Newman spent 26 years at PepsiCo, where he served in a variety of finance leadership roles spanning Europe, Asia and North and South America. He also served as Executive Vice President for PepsiCo's Global Operations, responsible for global operations including supply chain, global procurement, global security, enterprise risk management and transformation, and as PepsiCo's Chief Strategy Officer.
- Prem S. Shah
Prem S. Shah，自2024年11月起担任CVS Health Corporation的执行副总裁兼集团总裁；从2021年11月到2024年11月担任CVS Health Corporation的执行副总裁兼首席药房官，从2022年1月到2024年11月担任零售总裁或联席总裁；从2018年8月到2021年11月，CVS Caremark执行副总裁，专业和产品创新；从2013年2月到2018年7月，CVS Caremark担任专业药房副总裁。
Prem S. Shah,Executive Vice President and Group President of CVS Health Corporation since November 2024; Executive Vice President and Chief Pharmacy Officer of CVS Health Corporation from November 2021 through November 2024 and President or Co-President of Retail from January 2022 through November 2024; Executive Vice President, Specialty and Product Innovation, CVS Caremark from August 2018 through November 2021; Vice President - Specialty Pharmacy, CVS Caremark from February 2013 through July 2018.- Prem S. Shah，自2024年11月起担任CVS Health Corporation的执行副总裁兼集团总裁；从2021年11月到2024年11月担任CVS Health Corporation的执行副总裁兼首席药房官，从2022年1月到2024年11月担任零售总裁或联席总裁；从2018年8月到2021年11月，CVS Caremark执行副总裁，专业和产品创新；从2013年2月到2018年7月，CVS Caremark担任专业药房副总裁。
- Prem S. Shah,Executive Vice President and Group President of CVS Health Corporation since November 2024; Executive Vice President and Chief Pharmacy Officer of CVS Health Corporation from November 2021 through November 2024 and President or Co-President of Retail from January 2022 through November 2024; Executive Vice President, Specialty and Product Innovation, CVS Caremark from August 2018 through November 2021; Vice President - Specialty Pharmacy, CVS Caremark from February 2013 through July 2018.
- Tilak Mandadi
Tilak Mandadi，自2022年7月起担任CVS Health Corporation的风险投资执行副总裁兼首席数字、数据、分析和技术官；2021年7月至2022年7月，担任MGM Resorts International首席战略官；2013年3月至2021年7月，担任迪士尼乐园、体验和产品的执行副总裁、数字和全球首席技术官。
Tilak Mandadi,Executive Vice President, Ventures and Chief Digital, Data, Analytics and Technology Officer of CVS Health Corporation since July 2022; Chief Strategy Officer, MGM Resorts International from July 2021 through July 2022; Executive Vice President, Digital & Global Chief Technology Officer, Disney Parks, Experiences and Products from March 2013 through July 2021.- Tilak Mandadi，自2022年7月起担任CVS Health Corporation的风险投资执行副总裁兼首席数字、数据、分析和技术官；2021年7月至2022年7月，担任MGM Resorts International首席战略官；2013年3月至2021年7月，担任迪士尼乐园、体验和产品的执行副总裁、数字和全球首席技术官。
- Tilak Mandadi,Executive Vice President, Ventures and Chief Digital, Data, Analytics and Technology Officer of CVS Health Corporation since July 2022; Chief Strategy Officer, MGM Resorts International from July 2021 through July 2022; Executive Vice President, Digital & Global Chief Technology Officer, Disney Parks, Experiences and Products from March 2013 through July 2021.
- Amy Compton Philips
Amy Compton飞利浦，自2025年5月起担任西维斯健康公司执行副总裁兼首席医疗官。在加入公司之前，康普顿-飞利浦博士最近于2022年9月至2025年4月担任Press Ganey的首席医师执行官，Press Ganey是一家以开发和分发患者满意度调查而闻名的医疗保健公司，并于2015年8月至2022年9月担任Providence Health System的首席临床官，负责临床运营、质量、药房和临床研究所。
Amy Compton Philips,has been the Executive Vice President and Chief Medical Officer of CVS Health Corporation since May 2025. Prior to joining the Company, Dr. Compton-Philips was most recently the Chief Physician Executive of Press Ganey, a health care company known for developing and distributing patient satisfaction surveys, from September 2022 to April 2025 and the Chief Clinical Officer of Providence Health System, responsible for clinical operation, quality, pharmacy and clinical institutes from August 2015 to September 2022.- Amy Compton飞利浦，自2025年5月起担任西维斯健康公司执行副总裁兼首席医疗官。在加入公司之前，康普顿-飞利浦博士最近于2022年9月至2025年4月担任Press Ganey的首席医师执行官，Press Ganey是一家以开发和分发患者满意度调查而闻名的医疗保健公司，并于2015年8月至2022年9月担任Providence Health System的首席临床官，负责临床运营、质量、药房和临床研究所。
- Amy Compton Philips,has been the Executive Vice President and Chief Medical Officer of CVS Health Corporation since May 2025. Prior to joining the Company, Dr. Compton-Philips was most recently the Chief Physician Executive of Press Ganey, a health care company known for developing and distributing patient satisfaction surveys, from September 2022 to April 2025 and the Chief Clinical Officer of Providence Health System, responsible for clinical operation, quality, pharmacy and clinical institutes from August 2015 to September 2022.
- Steven H. Nelson
Steven H. Nelson自2010年11月起担任公司董事。Nelson自2008年8月起担任West Region of UnitedHealthCare（UnitedHealth Group一个运营分部，健康福利和服务供应商）首席执行官。Nelson从2007年12月到2008年8月担任AmeriChoice（UnitedHealth Group一家子公司）总裁。他从2004年10月到2007年12月担任HealthNet（一家医疗保健公司）东部地区总裁和高级产品分部总裁。Nelson从1998年6月到1998年12月在Henry Ford Health System（一家非盈利组织）担任多个执行职位。Nelson持有Portland State University文学学士学位；the University of Michigan工商管理和医疗保健管理硕士学位。
Steven H. Nelson is Executive Vice President of UnitedHealth Group and Chief Executive Officer of UnitedHealthcare and has served in that capacity since August 2017. Mr. Nelson served as Chief Executive Officer of UnitedHealthcare's Medicare & Retirement, from March 2014 to August 2017. He served as Chief Executive Officer of UnitedHealthcare Community & State from August 2012 to March 2014. From January 2008 to July 2012 he served as President of UnitedHealthcare Community & State and then Chief Executive Officer of UnitedHealthcare Employer & Individual's West Region business.Nelson holds a Bachelor of Arts degree from Portland State University; and a Master of Business Administration and Healthcare Administration degree from the University of Michigan.- Steven H. Nelson自2010年11月起担任公司董事。Nelson自2008年8月起担任West Region of UnitedHealthCare（UnitedHealth Group一个运营分部，健康福利和服务供应商）首席执行官。Nelson从2007年12月到2008年8月担任AmeriChoice（UnitedHealth Group一家子公司）总裁。他从2004年10月到2007年12月担任HealthNet（一家医疗保健公司）东部地区总裁和高级产品分部总裁。Nelson从1998年6月到1998年12月在Henry Ford Health System（一家非盈利组织）担任多个执行职位。Nelson持有Portland State University文学学士学位；the University of Michigan工商管理和医疗保健管理硕士学位。
- Steven H. Nelson is Executive Vice President of UnitedHealth Group and Chief Executive Officer of UnitedHealthcare and has served in that capacity since August 2017. Mr. Nelson served as Chief Executive Officer of UnitedHealthcare's Medicare & Retirement, from March 2014 to August 2017. He served as Chief Executive Officer of UnitedHealthcare Community & State from August 2012 to March 2014. From January 2008 to July 2012 he served as President of UnitedHealthcare Community & State and then Chief Executive Officer of UnitedHealthcare Employer & Individual's West Region business.Nelson holds a Bachelor of Arts degree from Portland State University; and a Master of Business Administration and Healthcare Administration degree from the University of Michigan.
- Samrat S. Khichi
Samrat S. Khichi，自2023年2月起担任CVS Health Corporation的执行副总裁、首席政策官和总法律顾问；从2017年12月到2023年2月，担任全球医疗技术公司Becton Dickinson Company（“BD”）的执行副总裁，负责企业发展、公共政策、监管事务和总法律顾问；从2014年7月到2017年12月，担任C.R. Bard（一家从BD收购的医疗技术公司）的高级副总裁、总法律顾问兼秘书。
Samrat S. Khichi,Executive Vice President, Chief Policy Officer and General Counsel of CVS Health Corporation since February 2023; Executive Vice President, Corporate Development, Public Policy, Regulatory Affairs and General Counsel of Becton Dickinson Company ("BD"), a global medical technology company, from December 2017 through February 2023; Senior Vice President, General Counsel and Secretary of C.R. Bard, a medical technology company that was acquired from BD, from July 2014 through December 2017.- Samrat S. Khichi，自2023年2月起担任CVS Health Corporation的执行副总裁、首席政策官和总法律顾问；从2017年12月到2023年2月，担任全球医疗技术公司Becton Dickinson Company（“BD”）的执行副总裁，负责企业发展、公共政策、监管事务和总法律顾问；从2014年7月到2017年12月，担任C.R. Bard（一家从BD收购的医疗技术公司）的高级副总裁、总法律顾问兼秘书。
- Samrat S. Khichi,Executive Vice President, Chief Policy Officer and General Counsel of CVS Health Corporation since February 2023; Executive Vice President, Corporate Development, Public Policy, Regulatory Affairs and General Counsel of Becton Dickinson Company ("BD"), a global medical technology company, from December 2017 through February 2023; Senior Vice President, General Counsel and Secretary of C.R. Bard, a medical technology company that was acquired from BD, from July 2014 through December 2017.